Status:
COMPLETED
Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab
Lead Sponsor:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Conditions:
Neterton Syndrome
Eligibility:
All Genders
Up to 18 years
Brief Summary
In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome.
Detailed Description
Pediatric patients qualified for participation in the study if they had a documented diagnosis of Neterton syndrome and they received treatment with sekukinumab or dupilumab for at least 3 months. Al...
Eligibility Criteria
Inclusion
- Pediatric patients with Neterton syndrome
- Treatment with secukinumab and/or dupilumab for at least 3 months
Exclusion
- Irregular administration of therapy
- Development of a serious adverse event
Key Trial Info
Start Date :
December 19 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 10 2025
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT07151508
Start Date
December 19 2023
End Date
January 10 2025
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology
Moscow, Russia